The FDA has approved Botox for the treatment of lower limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. The treatment was already approved for ...

The US Food and Drug Administration (FDA) has approved onabotulinumtoxinA (Botox, Allergan) to ease lower-limb spasticity in children and adolescents aged 2 years to 17 years, excluding spasticity ...

Allergan announced that the Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Applications (sBLAs) for Botox (onabotulinumtoxinA) injection for the ...

- BOTOX® is the First and Only FDA-Approved Neurotoxin Treatment for Both Upper and Lower Limb Spasticity - DUBLIN, Jan. 22, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global ...

Cerebral Palsy has been linked to a condition called cryptorchidism in males - when one or both of the testicles are not present in the scrotum. A new study in Developmental Medicine & Child Neurology ...

– Dysport is the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity1 – – Pivotal Phase 3 study demonstrated Dysport improved spasticity ...

DUBLIN, Oct. 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) ...

The NICE-Wide Prioritisation Board met on 20 November 2025 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access ...

Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its Supplemental Biologics ...